• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

射血分数降低的心力衰竭随机临床试验中缺血病因的特征:一项系统评价和荟萃分析。

Characterization of ischemic etiology in heart failure with reduced ejection fraction randomized clinical trials: A systematic review and meta-analysis.

作者信息

Canepa Marco, Anastasia Gianluca, Ameri Pietro, Vergallo Rocco, O'Connor Christopher M, Sinagra Gianfranco, Porto Italo

机构信息

Cardiovascular Unit, Department of Internal Medicine, University of Genova, Italy; Cardiovascular Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Cardiovascular Unit, Department of Internal Medicine, University of Genova, Italy.

出版信息

Eur J Intern Med. 2025 Apr;134:51-58. doi: 10.1016/j.ejim.2025.02.004. Epub 2025 Feb 11.

DOI:10.1016/j.ejim.2025.02.004
PMID:39939263
Abstract

AIMS

We investigated how ischemic etiology has been assigned in heart failure with a reduced ejection fraction (HFrEF) randomized controlled trials (RCTs).

METHODS AND RESULTS

We performed a systematic review and meta-analysis of definitions, rates of ischemic etiology and of each ischemic definition component: i) coronary artery disease (CAD), ii) myocardial infarction (MI), iii) coronary revascularization, and iv) prior/current angina. A total of 145 HFrEF RCTs were selected, of which 133 (91.7 %) enrolling both ischemic and non-ischemic patients (629 patients/study on average, median age 64.8 years and ejection fraction 28.2 %). The majority of these RCTs (84.2 %) lacked of clear ischemic etiology definition. Rate of ischemic etiology was 57.8 % (122 RCTs, 169,855 patients), of CAD 53.8 % (25 RCTs, 18,756 patients), of prior MI 46.7 % (57 RCTs, 80,582 patients), of prior revascularization 39.9 % (32 RCTs, 30,730 patients), and of prior/current angina 25.5 % (22 RCTs, 25,572 patients). In studies presenting both variables, prior MI showed the strongest correlations with assigned ischemic etiology (β = 0.84, p < 0.0001, 49 RCTs), followed by prior/current angina (β = 0.84, p < 0.0001, 20 RCTs), prior revascularization (β = 0.30, p = 0.006, 28 RCTs), whereas CAD had no significant correlation (β = 0.29, p = 0.162, from 17 RCTs). Rate of prior MI decreased over time (1986-2007: 51.4 ± 11.6 %; 2008-2016: 48.2 ± 8.8 %; 2017-2023: 41.4 ± 16.6 %; p = 0.057), whereas the one of prior revascularization increased (28.3 ± 11.2 %; 40.7 ± 19.6 %; 49.3 ± 19.4 %; p = 0.048).

CONCLUSIONS

An accurate definition of ischemic etiology is mostly lacking in HFrEF RCTs, and primarily assigned based on investigators clinical judgment, sometimes in the presence of a prior MI, although the rate of this component showed a decline over time.

摘要

目的

我们研究了在射血分数降低的心力衰竭(HFrEF)随机对照试验(RCT)中,缺血性病因是如何确定的。

方法与结果

我们对缺血性病因的定义、发生率以及每个缺血性定义组成部分进行了系统评价和荟萃分析:i)冠状动脉疾病(CAD),ii)心肌梗死(MI),iii)冠状动脉血运重建,iv)既往/当前心绞痛。共筛选出145项HFrEF RCT,其中133项(91.7%)纳入了缺血性和非缺血性患者(平均每项研究629例患者,中位年龄64.8岁,射血分数28.2%)。这些RCT中的大多数(84.2%)缺乏明确的缺血性病因定义。缺血性病因的发生率为57.8%(122项RCT,169,855例患者),CAD为53.8%(25项RCT,18,756例患者),既往MI为46.7%(57项RCT,80,582例患者),既往血运重建为39.9%(32项RCT,30,730例患者),既往/当前心绞痛为25.5%(22项RCT,25,572例患者)。在同时呈现这两个变量的研究中,既往MI与指定的缺血性病因相关性最强(β = 0.84,p < 0.0001,49项RCT),其次是既往/当前心绞痛(β = 0.84,p < 0.0001,20项RCT),既往血运重建(β = 0.30,p = 0.006,28项RCT),而CAD无显著相关性(β = 0.29,p = 0.162,17项RCT)。既往MI的发生率随时间下降(1986 - 2007年:51.4 ± 11.6%;2008 - 2016年:48.2 ± 8.8%;2017 - 2023年:41.4 ± 16.6%;p = 0.057),而既往血运重建的发生率则上升(28.3 ± 11.2%;40.7 ± 19.6%;49.3 ± 19.4%;p = 0.048)。

结论

HFrEF RCT大多缺乏缺血性病因的准确定义,主要基于研究者的临床判断来确定,有时是在存在既往MI的情况下,尽管该组成部分的发生率随时间呈下降趋势。

相似文献

1
Characterization of ischemic etiology in heart failure with reduced ejection fraction randomized clinical trials: A systematic review and meta-analysis.射血分数降低的心力衰竭随机临床试验中缺血病因的特征:一项系统评价和荟萃分析。
Eur J Intern Med. 2025 Apr;134:51-58. doi: 10.1016/j.ejim.2025.02.004. Epub 2025 Feb 11.
2
Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease).射血分数保留的心力衰竭:有和无心绞痛患者的比较(来自杜克心血管疾病数据库)。
J Am Coll Cardiol. 2014 Jan 28;63(3):251-8. doi: 10.1016/j.jacc.2013.09.039. Epub 2013 Oct 23.
3
Revascularization in Ischemic Heart Failure with Reduced Left Ventricular Ejection Fraction.左心室射血分数降低的缺血性心力衰竭中的血运重建
Curr Cardiol Rep. 2023 May;25(5):401-409. doi: 10.1007/s11886-023-01860-3. Epub 2023 Apr 3.
4
Hypotheses, rationale, design, and methods for prognostic evaluation of a randomized comparison between patients with coronary artery disease associated with ischemic cardiomyopathy who undergo medical or surgical treatment: MASS-VI (HF).冠心病合并缺血性心肌病患者接受药物或手术治疗的随机对照预后评估的假设、理论依据、设计及方法:MASS-VI(心力衰竭)研究
Trials. 2020 Apr 16;21(1):337. doi: 10.1186/s13063-020-04270-w.
5
Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial.丹麦试验:心肌梗死后无射血分数降低的β受体阻滞剂治疗的设计和原理:一项随机对照试验的研究方案。
Trials. 2020 May 23;21(1):415. doi: 10.1186/s13063-020-4214-6.
6
Survival Benefits of Invasive Versus Conservative Strategies in Heart Failure in Patients With Reduced Ejection Fraction and Coronary Artery Disease: A Meta-Analysis.射血分数降低且患有冠状动脉疾病的心力衰竭患者中,侵入性策略与保守策略的生存获益:一项荟萃分析。
Circ Heart Fail. 2017 Jan;10(1). doi: 10.1161/CIRCHEARTFAILURE.116.003255.
7
Effectiveness and Safety of Extracorporeal Shockwave Myocardial Revascularization in Patients With Refractory Angina Pectoris and Heart Failure.体外冲击波心肌血运重建术治疗难治性心绞痛和心力衰竭患者的有效性和安全性
Am J Cardiol. 2021 Apr 1;144:26-32. doi: 10.1016/j.amjcard.2020.12.065. Epub 2020 Dec 29.
8
Colchicine may become a new cornerstone therapy for coronary artery disease: a meta-analysis of randomized controlled trials.秋水仙碱可能成为冠状动脉疾病的新基石治疗方法:一项随机对照试验的荟萃分析。
Clin Rheumatol. 2022 Jun;41(6):1873-1887. doi: 10.1007/s10067-022-06050-0. Epub 2022 Feb 9.
9
Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials.常规血运重建与稳定型缺血性心脏病初始药物治疗的比较:随机试验的系统评价和荟萃分析。
Circulation. 2020 Sep;142(9):841-857. doi: 10.1161/CIRCULATIONAHA.120.048194. Epub 2020 Jun 26.
10
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design.国际比较医疗与介入治疗缺血效果研究(ISCHEMIA)试验:原理与设计。
Am Heart J. 2018 Jul;201:124-135. doi: 10.1016/j.ahj.2018.04.011. Epub 2018 Apr 21.

引用本文的文献

1
The Level of Apolipoprotein A-I Is Associated with a Prognosis in Patients with Chronic Heart Failure Especially in HFmrEF and HFpEF: A Retrospective Cohort Study.载脂蛋白A-I水平与慢性心力衰竭患者尤其是射血分数保留的心力衰竭(HFpEF)和射血分数中间值的心力衰竭(HFmrEF)患者的预后相关:一项回顾性队列研究。
Int J Gen Med. 2025 Aug 25;18:4735-4751. doi: 10.2147/IJGM.S531156. eCollection 2025.
2
Allogeneic, Xenogeneic, and Exogenic Hearts for Transplantation.用于移植的同种异体、异种和外源性心脏。
Methodist Debakey Cardiovasc J. 2025 May 15;21(3):92-99. doi: 10.14797/mdcvj.1590. eCollection 2025.